The diagnostic kit sitting on a laboratory shelf is only as good as the specimen that reaches it. In the monkeypox testing landscape, the unglamorous discipline of swab selection, lesion sampling, and cold-chain handling has emerged as a decisive and frequently overlooked force shaping which kits gain traction and which falter.
The U.S. Centers for Disease Control and Prevention is explicit: only sterile synthetic swabs with plastic, wood, or thin aluminum shafts are acceptable; cotton swabs and foam-tipped devices can inhibit PCR and render results inconclusive. This is not a minor technical footnote. It is a gatekeeping criterion that determines whether a kit’s claimed sensitivity survives contact with real clinical specimens.
The consequences of getting this wrong are measurable. A multicentre field evaluation conducted across sixteen sites in the Democratic Republic of the Congo and Uganda between January and April 2025 tested the NG-Test Monkeypox antigen rapid diagnostic test against PCR reference standards. Overall sensitivity reached 70.4%, but the gap between countries was stark: 81.9% in Uganda versus 55.1% in DR Congo. Specificity similarly diverged, at 86.5% and 91.7% respectively.
The authors attributed part of this variation to operational realities specimen quality, lesion stage, and the sheer difficulty of maintaining protocol fidelity in settings affected by conflict and displacement. For kit manufacturers, the message is uncomfortable but clear: performance data generated in well-resourced reference laboratories may not transfer to the front lines where mpox detection matters most.
When the Label Says “Clade I/II” but the Kit Cannot Tell Them Apart
-
A quiet regulatory paradox sits at the heart of the current kit landscape. The World Health Organization’s Target Product Profiles have identified clade differentiation as a preferred characteristic for mpox diagnostics, yet as of the most recent Emergency Use Listing updates, no kit authorized under WHO EUL or CDC EUA possesses this capability.
-
The WHO’s own product information for the Bioperfectus Monkeypox Virus Fast Real Time PCR Kit listed for procurement in December 2025 states plainly that the assay is “capable of detection but not differentiation of Monkeypox virus clade I and clade II”.
-
This is not an isolated gap. It reflects the broader technical difficulty of designing primers that reliably distinguish between clades without compromising sensitivity.
-
The clinical stakes are not abstract. Clade I mpox has been associated with more severe disease, and the European Centre for Disease Prevention and Control has urged laboratories to perform molecular genotyping of detected strains and share sequences in public databases.
-
When a kit returns a positive result without clade information, public health authorities are left with a diagnostic answer that is clinically useful but epidemiologically incomplete. The kit market, in other words, is currently delivering tools that answer the first question “is this mpox?” while leaving the second “which mpox?” to under-resourced sequencing networks.
Curious about the report? Dive into our newest updated version at no cost: https://www.24lifesciences.com/monkeypox-diagnostic-kit-market-13110
Home Collection Enters the Regulatory Record
In March 2026, the U.S. Food and Drug Administration granted a revision to Labcorp’s Emergency Use Authorization for its Monkeypox PCR Test Home Collection Kit, accepting additional clinical specimen data submitted to fulfill a condition of authorization originally issued in July 2024.
The significance lies less in the specific data than in the precedent: a home-collection model for mpox testing has moved from emergency accommodation to a reviewed, condition-satisfied regulatory status. For a disease whose lesions can appear in intimate anatomical sites and whose patients may understandably hesitate to present at a clinic, the availability of a validated self-collection pathway changes the calculus of testing access.
Yet home collection introduces a new variable into the kit performance equation: the patient as specimen collector. The CDC’s instructions are demanding vigorous swabbing of each lesion, two swabs per lesion from different body locations, avoidance of sharps, parafilm around lids.
Whether a kit’s analytical sensitivity holds up when the swab is wielded by an untrained hand remains a question that no emergency use listing can fully answer. The Labcorp authorization signals regulatory acceptance of the model, but the post-market evidence will determine whether home collection expands the mpox testing envelope or creates a new category of inconclusive results.
The Procurement List as a Map of Quality-Assured Capacity
-
The WHO Emergency Use Listing roster has grown incrementally rather than explosively. As of late 2025, the twelfth MPXV assay Jiangsu Bioperfectus’s Fast Real Time PCR Kit achieved EUL status, joining a list that remains short relative to the scale of the 2022 outbreak response.
-
A subsequent listing in 2026 added DiaCarta’s QuantiVirus MPXV Test Kit.
-
For procurement officers in low- and middle-income countries, this list functions as a de facto quality filter: EUL status means the kit has undergone WHO review and is eligible for UN procurement.
-
The absence of a product from the list is not proof of inadequacy, but it does mean that ministries of health relying on international financing have a narrow menu from which to choose.
-
This concentration has consequences. When only a dozen or so assays carry EUL recognition, supply chain disruptions or manufacturing delays at any single producer can ripple across national testing programs.
The situation report format maintained by WHO now in its sixty-fourth iteration as of March 2026 tracks the epidemiological picture, but the diagnostic supply picture moves on a different clock, one governed by dossier reviews and quality management audits rather than case counts.
The kit market’s resilience, in other words, depends less on the number of products in development than on the number that have crossed the regulatory threshold into procurable status.